

K012596

Pg 1 of 2

FEB 14 2002

SECTION 2. SUMMARY AND CERTIFICATION

A. 510(K) SUMMARY

Submitter: SterilMed, Inc.

Contact Person: Patrick Fleischhacker
SterilMed, Inc.
11400 73rd Avenue North
Minneapolis, MN 55369
Ph: 763-488-3400
Fax: 763-488-3350

Date Prepared: August 8, 2001

Trade Name: Reprocessed Hot Biopsy Forceps

**Classification Name:
and Number:** Biopsy Forceps, Electric
Class II, 21 CFR 876.4300

Product Code: KGE

Predicate Device(s): The reprocessed hot biopsy forceps are substantially equivalent to: "Thermal Option" Hot Biopsy Forceps (K932790), manufactured by Ballard (formerly Cox); Hot Biopsy Forceps (K925361), manufactured by US Endoscopy; and "Radial Jaw" Hot Biopsy Forceps (K860366), manufactured by Microvasive; and the "Precisor" Hot Biopsy Forceps (K905088), manufactured by Bard (formerly ESCO).

The devices identified as predicate devices are for the purpose of establishing substantial equivalence only, they are not necessarily included in the list of devices for which clearance to reprocess has been granted.

Device Description:

The device consists of a proximal handle containing an electrosurgical plug which is connected, via a coil, spring or rod mechanism, to the biopsy cup or alligator forceps at the distal tip. The biopsy forceps range from 100 to 240cm in length and 1.8-3.3mm in diameter. The jaws range from 1.8 to 3.3mm in diameter. The cup forceps may or may not have serrated edges, a fenestration, needle, or distal biting tooth.

K012596 pg 2 of 2

The forceps are covered with a sheath of electrical insulation. The electrosurgical plug on the handle used for connection to the appropriate electrosurgical unit. This submission does not include the electrosurgical box that the forceps connect to or its associated connecting cable.

Intended Use:

The reprocessed hot biopsy forceps are intended to be used for endoscopic tissue sample acquisition, controlled coagulation/cautery, and sessile polyp removal in the gastrointestinal tract.

Functional and Safety Testing:

Representative samples of reprocessed hot biopsy forceps underwent bench testing to demonstrate appropriate functional characteristics. Process validation testing was done to validate the cleaning and sterilization procedures as well as the device's packaging. In addition, the manufacturing process includes visual and functional testing of all products produced.

Conclusion:

The hot biopsy forceps reprocessed by SterilMed are substantially equivalent to the following specific predicate devices: "Thermal Option" Hot Biopsy Forceps (K932790), manufactured by Ballard (formerly Cox); Hot Biopsy Forceps (K925361), manufactured by US Endoscopy; "Radial Jaw" Hot Biopsy Forceps (K860366), manufactured by Microvasive; and the "Precisor" Hot Biopsy Forceps (K905088), manufactured by Bard (formerly ESCO). This conclusion is based upon the devices' similarities in functional design, materials, indications for use and methods of construction.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

FEB 14 2002

Mr. Patrick Fleischhacker
Vice President, Regulatory
and Quality
SterilMed, Inc.
11400 73rd Avenue North
MINNEAPOLIS MN 55369

Re: K012596
Trade/Device Name: SEE ENCLOSURE 1
Regulation Number: 21 CFR 876.4300
Regulation Name: Endoscopic electrosurgical
unit and accessories
Regulatory Class: II
Product Code: 78 KGE
Dated: December 6, 2001
Received: December 7, 2001

Dear Mr. Fleischhacker:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

K012596

Indications for Use Page

Device Name: Reprocessed Hot Biopsy Forceps

Indications for Use:

The reprocessed hot biopsy forceps are intended for use during endoscopic tissue sample acquisition, controlled coagulation/cautery, and sessile polyp removal in the gastrointestinal tract.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Nancy C. Brighton
(Division Sign-Off)
Division of Reproductive, Abdominal,
and Radiological Devices
510(k) Number K012596

Prescription Use ☒
(Per 21 CFR 801.109)